These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30461207)

  • 21. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG; Wagner W; Prott FJ
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
    Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
    Gu J; Zhu S; Li X; Wu H; Li Y; Hua F
    PLoS One; 2014; 9(5):e95968. PubMed ID: 24788761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
    Batcha M
    Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
    [No Abstract]   [Full Text] [Related]  

  • 29. Radiochemotherapy with amifostine cytoprotection for head and neck cancer.
    Büntzel J; Schuth J; Küttner K; Glatzel M
    Support Care Cancer; 1998 Mar; 6(2):155-60. PubMed ID: 9540175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
    Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
    Bourhis J; De Crevoisier R; Abdulkarim B; Deutsch E; Lusinchi A; Luboinski B; Wibault P; Eschwege F
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1105-8. PubMed ID: 10725619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
    Thorstad WL; Haughey B; Chao KS
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer].
    Grötz KA; Henneicke-von Zepelin HH; Kohnen R; al-Nawas B; Bockisch A; Kutzner J; Wüstenberg P; Naser-Hijazi B; Belz GG; Wagner W
    Strahlenther Onkol; 1999 Aug; 175(8):397-403; discussion 404. PubMed ID: 10481772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
    Anné PR; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer.
    Karacetin D; Yücel B; Leblebicioğlu B; Aksakal O; Maral O; Incekara O
    J BUON; 2004; 9(1):23-6. PubMed ID: 17385823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.